Gadolinium-based MRI contrast agents have been proving to carry great risk of
nephrogenic systemic fibrosis (NSF). This has caused the
U.S. Food and Drug Administration (FDA) to announce warning labels updates on three of these agents. The three agents are
Magnevist, sold by
Bayer Healthcare Pharmaceuticals of Wayne, NJ;
Omniscan, marketed by
GE Healthcare of Chalfont St. Giles, U.K.; and
Optimark, sold by
Covidien of Dublin, Ireland.
No comments:
Post a Comment